Zevra Therapeutics' drug, Miplyffa, for treating a rare and fatal genetic disorder will have a wholesale acquisition cost ranging between $40,000 and $106,000 per...
The US Food and Drug Administration (FDA) approved Miplyffa (arimoclomol), an oral medication for the treatment of Neimann-Pick disease, type C (NPC).
Miplyffa, in combination...